Cradle

, but the path to realizing its full potential remains 

 for many organizations. After working with 21+ biopharma companies and 30+ active programs, we've identified emerging patterns in how organizations succeed with GenAI in protein engineering.

This webinar shares our initial framework – not as a complete maturity model, but as a starting point for understanding the journey ahead. Cradle's CEO Stef van Grieken will present our early analysis of what separates organizations achieving 12x faster development from those still finding their way.

Most importantly: This is the beginning of a dialogue. We're sharing our analysis to spark conversation about how our industry can collectively define and achieve GenAI excellence.

Is your drug discovery ready for AI? A maturity model for GenAI in drug discovery [Live webinar]